Publications by authors named "Oswaldo F Moura Brasil"

2 Publications

  • Page 1 of 1

Regression of Macular Cavernous Hemangioma with Systemic Infliximab.

Ophthalmic Surg Lasers Imaging 2010 Mar 9:1-3. Epub 2010 Mar 9.

Cavernous hemangioma of the retina is an unusual vascular hamartoma that has been reported to occur either sporadically or as a dominantly inherited trait. A case of a large and sporadic macular cavernous hemangioma that was successfully treated with systemic infliximab as a first line of treatment is presented. The patient was referred with decreased vision of the right eye for 6 months. Fundus examination disclosed a reddish elevated lesion in the posterior pole that obscured the macula and encroached on the fovea. It consisted of grapelike aneurysms. The patient underwent treatment with infliximab intravenously. Two weeks after the second infusion of infliximab, visual acuity improved to 20/80 with a marked involution of the tumor in the right eye. Although the data are limited, we think that a new perspective for treatment of retinal vascular tumors may appear in the future considering antibodies to tumor necrosis factor (TNF)-alpha.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3928/15428877-20100215-34DOI Listing
March 2010

Regression of vasoproliferative tumor with systemic infliximab.

Ophthalmic Surg Lasers Imaging 2008 Jul-Aug;39(4):348-9

Pedro Ernesto University Hospital, State University of Rio de Janeiro, Rio de Janeiro, Brazil.

The anti-tumor necrosis factor (TNF) monoclonal antibody infliximab inhibits the pleiotropic actions of TNF and is widely used for the treatment of inflammatory diseases, such as uveitis. A pathogenetic role of TNF in ocular inflammatory conditions has recently emerged. The authors describe a patient with collagen mixed disease who had decreased vision in the left eye. Fundus examination disclosed bilateral peripheral vasoproliferative tumors and macular edema in the left eye. The patient underwent treatment with infliximab intravenously for his systemic condition. Regression of the vasoproliferative tumors in both eyes and improvement of macular edema in the left eye was observed. Although the data are limited, anti-TNF antibodies such as infliximab may be useful in the treatment of retinal vascular tumors.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3928/15428877-20080701-09DOI Listing
September 2008